Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Randomised, Parallel, Three Treatment Groups, Multicentre, Phase IV Study - in Real Life - to Compare the Change in Social Outcome of Quetiapine Fumarate (Seroquel®) Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia.

NCT00255515 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00255515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00255515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Randomised, Parallel, Three Treatment Groups, Multicentre, Phase IV Study - in Real Life - to Compare the Change in Social Outcome of Quetiapine Fumarate (Seroquel®) Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia.
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2005
Completion date
December 31, 2007
Enrollment
85 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia